George E. Peoples
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
George E. Peoples has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Sathibalan Ponniah
11 shared publications- Elizabeth A. Mittendorf
Department of Surgery, U.T.M.D. Anderson Cancer Center, Houston, TX
9 shared publications Jarrod P. Holmes
Department of Hematology and Medical Oncology, Naval Medical Center San Diego, San Diego, California, USA
7 shared publications- Alexander Stojadinovic
Uniformed Services University of the Health Sciences, Bethesda, MD, USA
6 shared publications Elizabeth A. Mittendorf
Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
6 shared publications- Guy T. Clifton
The University of Texas MD Anderson Cancer Center, Houston, TX
5 shared publications
Latest Publications
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 225 (4) , S23-S24
Final Analysis of a Randomized Phase 1b Trial to Assess Sequencing of the E39 and E39' Vaccines to Optimize Long-Term Antitumor Immunity in Folate Binding Protein (FBP) Expressing Tumors
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 225 (4) , S23-S24
Final Analysis of a Randomized Phase 1b Trial to Assess Sequencing of the E39 and E39' Vaccines to Optimize Long-Term Antitumor Immunity in Folate Binding Protein (FBP) Expressing Tumors
- 1 October 2016
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 223 (4) , S20-S21
Phase Ib Trial Comparing Different Doses and Schedules of a Folate-Binding Protein-Derived Peptide Vaccine, E39, and its Attenuated Version, E39’, to Induce Long-Term Folate-Binding Protein-Specific Immunity in Disease-Free Cancer Patients
- 1 October 2016
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 223 (4) , S20-S21
Phase Ib Trial Comparing Different Doses and Schedules of a Folate-Binding Protein-Derived Peptide Vaccine, E39, and its Attenuated Version, E39’, to Induce Long-Term Folate-Binding Protein-Specific Immunity in Disease-Free Cancer Patients
- 1 May 2016
- Vol. 30 (5) , 475-81, 485
Injecting Hope--A Review of Breast Cancer Vaccines.
There is significant interest in investigating immunotherapeutic strategies to be used for the treatment of breast cancer patients. One form of immunotherapy under active investigation is the cancer vaccine. Vaccines are a form of active immune therapy designed to stimulate the immune system to recognize tumor cells as foreign. Vaccines include an antigen that serves as the target for the immune response, and an immunoadjuvant, which is a nonspecific stimulator of the immune response that promotes an environment conducive to immune stimulation. Vaccines are an appealing therapeutic strategy because they are specific and are associated with minimal toxicity. In addition, they stimulate the adaptive immune system, thereby producing a memory response allowing for sustained effect without repeated therapy. Currently, there are no US Food and Drug Administration-approved breast cancer vaccines; however, there are multiple vaccines and treatment strategies employing these vaccines that are being actively investigated in clinical trials.
- 1 May 2016
- Vol. 30 (5) , 475-81, 485
Injecting Hope--A Review of Breast Cancer Vaccines.
There is significant interest in investigating immunotherapeutic strategies to be used for the treatment of breast cancer patients. One form of immunotherapy under active investigation is the cancer vaccine. Vaccines are a form of active immune therapy designed to stimulate the immune system to recognize tumor cells as foreign. Vaccines include an antigen that serves as the target for the immune response, and an immunoadjuvant, which is a nonspecific stimulator of the immune response that promotes an environment conducive to immune stimulation. Vaccines are an appealing therapeutic strategy because they are specific and are associated with minimal toxicity. In addition, they stimulate the adaptive immune system, thereby producing a memory response allowing for sustained effect without repeated therapy. Currently, there are no US Food and Drug Administration-approved breast cancer vaccines; however, there are multiple vaccines and treatment strategies employing these vaccines that are being actively investigated in clinical trials.
- 1 October 2015
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 221 (4) , S18-S19
Correlation between Robust Local Reactions Prompting GM-CSF Dose Reduction to Clinical Response in a Phase II Trial of the GP2+GM-CSF HER2 Peptide Vaccine to Prevent Breast Cancer Recurrence
- 1 October 2015
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 221 (4) , S18-S19
Correlation between Robust Local Reactions Prompting GM-CSF Dose Reduction to Clinical Response in a Phase II Trial of the GP2+GM-CSF HER2 Peptide Vaccine to Prevent Breast Cancer Recurrence
- 1 October 2014
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 219 (4) , e170
Clinical benefit and safety of boosting the HER2 peptide vaccine (AE37+GM-CSF) in the adjuvant setting to prevent breast cancer recurrence
- 1 October 2014
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 219 (4) , e170
Clinical benefit and safety of boosting the HER2 peptide vaccine (AE37+GM-CSF) in the adjuvant setting to prevent breast cancer recurrence
- 1 October 2014
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 219 (4) , e47
Biomarker correlation to clinical response in a phase II trial of the HER2 peptide vaccine (AE37+GM-CSF)
- 1 October 2014
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 219 (4) , e47
Biomarker correlation to clinical response in a phase II trial of the HER2 peptide vaccine (AE37+GM-CSF)
- 30 September 2013
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 217 (3) , S134
Identification of a regulatory T cell subset that correlates with in vivo and in vitro immune responses in breast cancer patients receiving a CD4-eliciting, HER2 peptide vaccine (AE37)
- 30 September 2013
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 217 (3) , S134
Identification of a regulatory T cell subset that correlates with in vivo and in vitro immune responses in breast cancer patients receiving a CD4-eliciting, HER2 peptide vaccine (AE37)
- Open Access
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine
BACKGROUND: The authors are conducting clinical trials of the HER‐2/neu E75‐peptide vaccine in clinically disease‐free breast cancer (BC) patients. Their phase 1‐2 trials revealed that the E75 + granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) vaccine is safe and effective in stimulating clonal expansion of E75‐specific CD8+ T cells. They assessed the need for and response to a booster after completion of primary vaccination series.METHODS: BC patients enrolled in the E75 vaccine trials who were ≥6 months from completion of their primary vaccination series were offered boosters with E75 + GM‐CSF. Patients were monitored for toxicity. E75‐specific CD8+ T cells were quantified using the human leukocyte antigen‐A2:immunoglobulin G dimer before and after boosting.RESULTS: Fifty‐three patients received the vaccine booster. Median time from primary vaccination series was 9 months (range, 6‐35 months), and median residual E75‐specific immunity was 0.70% (range, 0‐3.49%) CD8+ lymphocytes. Elevated residual immunity (ERI) (CD8+ E75‐specific T cells >0.5%) was seen in 94.4% of patients at 6 months from primary vaccination series versus 48% of patients at >6 months (P = .002). The booster was well tolerated, with only grade 1 and 2 toxicity observed. Local reactions were more robust in patients receiving the booster at 6 months from primary vaccination series compared with those at >6 months (99.4 ± 6.1 mm vs 81.8 ± 4.1 mm, P = .01). In patients lacking ERI, 85% had increased ERI after vaccination (P = .0014).CONCLUSIONS: The HER‐2/neu E75 peptide vaccine E75 stimulates specific immunity in disease‐free BC patients. However, immunity wanes with time. A vaccine booster is safe and effective in stimulating E75‐specific immunity in those patients without ERI. These results suggest that the booster may be most effective at 6 months after completion of the primary vaccination series. Cancer 2011. Published 2010 by the American Cancer Society.
Open AccessUse of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine
BACKGROUND: The authors are conducting clinical trials of the HER‐2/neu E75‐peptide vaccine in clinically disease‐free breast cancer (BC) patients. Their phase 1‐2 trials revealed that the E75 + granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) vaccine is safe and effective in stimulating clonal expansion of E75‐specific CD8+ T cells. They assessed the need for and response to a booster after completion of primary vaccination series.METHODS: BC patients enrolled in the E75 vaccine trials who were ≥6 months from completion of their primary vaccination series were offered boosters with E75 + GM‐CSF. Patients were monitored for toxicity. E75‐specific CD8+ T cells were quantified using the human leukocyte antigen‐A2:immunoglobulin G dimer before and after boosting.RESULTS: Fifty‐three patients received the vaccine booster. Median time from primary vaccination series was 9 months (range, 6‐35 months), and median residual E75‐specific immunity was 0.70% (range, 0‐3.49%) CD8+ lymphocytes. Elevated residual immunity (ERI) (CD8+ E75‐specific T cells >0.5%) was seen in 94.4% of patients at 6 months from primary vaccination series versus 48% of patients at >6 months (P = .002). The booster was well tolerated, with only grade 1 and 2 toxicity observed. Local reactions were more robust in patients receiving the booster at 6 months from primary vaccination series compared with those at >6 months (99.4 ± 6.1 mm vs 81.8 ± 4.1 mm, P = .01). In patients lacking ERI, 85% had increased ERI after vaccination (P = .0014).CONCLUSIONS: The HER‐2/neu E75 peptide vaccine E75 stimulates specific immunity in disease‐free BC patients. However, immunity wanes with time. A vaccine booster is safe and effective in stimulating E75‐specific immunity in those patients without ERI. These results suggest that the booster may be most effective at 6 months after completion of the primary vaccination series. Cancer 2011. Published 2010 by the American Cancer Society.
- Open Access
Results of the first phase 1 clinical trial of the HER‐2/neu peptide (GP2) vaccine in disease‐free breast cancer patients
BACKGROUND: HER‐2/neu, overexpressed in breast cancer, is a source of immunogenic peptides that include GP2 and E75. Phase 2 testing of E75 as an adjuvant vaccine has suggested a clinical benefit. GP2, derived from the transmembrane portion of HER‐2/neu, has differing binding characteristics and may be more immunogenic than E75. Results of the first phase 1 trial of GP2 peptide vaccine are presented.METHODS: Disease‐free, lymph node‐negative, human leukocyte antigen (HLA)‐A2+ breast cancer patients were enrolled. This dose escalation trial included 4 groups to determine safety and optimal GP2 peptide/granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) dose. Toxicities were monitored. Immunologic response was assessed ex vivo via the HLA‐A2:immunoglobulin dimer assay to detect GP2‐specific CD8+ T cells (and E75‐specific CD8+ T cells to assess epitope spreading) and in vivo via delayed type hypersensitivity (DTH) reaction (medians/ranges).RESULTS: Eighteen patients were enrolled. All toxicities were grade ≤2. Eight (88.9%) of 9 patients in the first 3 dose groups required GM‐CSF dose reductions for local reactions ≥100 mm or grade ≥2 systemic toxicity. GM‐CSF dose was reduced to 125 μg for the final dose group. All patients responded immunologically ex vivo (GP2‐specific CD8+ T cells from prevaccination to maximum, 0.4% [0.0%‐2.0%] to 1.1% [0.4%‐3.6%], P < .001) and in vivo (GP2 pre‐ to postvaccination DTH, 0 mm [0.0‐19.5 mm] to 27.5 mm [0.0‐114.5 mm, P < .001). E75‐specific CD8+ T cells also increased in response to GP2 from prevaccination to maximum (0.8% [0.0%‐2.41%] to 1.6% [0.86%‐3.72%], P < .001).CONCLUSIONS: The GP2 peptide vaccine appears safe and well tolerated with minimal local/systemic toxicity. GP2 elicited HER‐2/neu–specific immune responses, including epitope spreading, in high‐risk, lymph node‐negative breast cancer patients. These findings support further investigation of the GP2 vaccine for the prevention of breast cancer recurrence. Cancer 2010. © 2010 American Cancer Society.
Open AccessResults of the first phase 1 clinical trial of the HER‐2/neu peptide (GP2) vaccine in disease‐free breast cancer patients
BACKGROUND: HER‐2/neu, overexpressed in breast cancer, is a source of immunogenic peptides that include GP2 and E75. Phase 2 testing of E75 as an adjuvant vaccine has suggested a clinical benefit. GP2, derived from the transmembrane portion of HER‐2/neu, has differing binding characteristics and may be more immunogenic than E75. Results of the first phase 1 trial of GP2 peptide vaccine are presented.METHODS: Disease‐free, lymph node‐negative, human leukocyte antigen (HLA)‐A2+ breast cancer patients were enrolled. This dose escalation trial included 4 groups to determine safety and optimal GP2 peptide/granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) dose. Toxicities were monitored. Immunologic response was assessed ex vivo via the HLA‐A2:immunoglobulin dimer assay to detect GP2‐specific CD8+ T cells (and E75‐specific CD8+ T cells to assess epitope spreading) and in vivo via delayed type hypersensitivity (DTH) reaction (medians/ranges).RESULTS: Eighteen patients were enrolled. All toxicities were grade ≤2. Eight (88.9%) of 9 patients in the first 3 dose groups required GM‐CSF dose reductions for local reactions ≥100 mm or grade ≥2 systemic toxicity. GM‐CSF dose was reduced to 125 μg for the final dose group. All patients responded immunologically ex vivo (GP2‐specific CD8+ T cells from prevaccination to maximum, 0.4% [0.0%‐2.0%] to 1.1% [0.4%‐3.6%], P < .001) and in vivo (GP2 pre‐ to postvaccination DTH, 0 mm [0.0‐19.5 mm] to 27.5 mm [0.0‐114.5 mm, P < .001). E75‐specific CD8+ T cells also increased in response to GP2 from prevaccination to maximum (0.8% [0.0%‐2.41%] to 1.6% [0.86%‐3.72%], P < .001).CONCLUSIONS: The GP2 peptide vaccine appears safe and well tolerated with minimal local/systemic toxicity. GP2 elicited HER‐2/neu–specific immune responses, including epitope spreading, in high‐risk, lymph node‐negative breast cancer patients. These findings support further investigation of the GP2 vaccine for the prevention of breast cancer recurrence. Cancer 2010. © 2010 American Cancer Society.
- 1 July 2009
- Vol. 29 (7) , 2427-35
N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells.
The objective of this study was to discover whether the peptides LRMK and LRMK-Ava linked to the N-terminus of peptides HER-2 (774-788) and HER-2 (776-788), respectively, help differentiation of E75-TCR(+)CD8(+) cells. Activation was quantified in terms of proliferation of E75-TCR(+)CD8(+) cells expressing high, medium and low density amounts of the specific TCR. Differentiation to functional CD8(+) cells was quantified as induction of Perforin (Perf), the lytic-enzyme which mediates the effector function of CD8(+) cells, in E75-TCR(+)CD8(+) cells. Peripheral blood mononuclear cells (PBMCs) of 3 patients activated with E75(+)AE-37 and E75(+)AE-47 more greatly increased the number of E75-TCR(Hi) CD8(+)Perf(+) cells than PBMCs activated by AE-47 alone or AE-47(+) E75. E75 plus cytokines and cytokines alone activated more E75-TCR(Low) cells than did AE-37 and AE-47. E75(+) AE-37 and AE-37 also induced differentiation of small- and medium-size activated CD8(+) cells from BRC ascites, in allogeneic activation, to Perf(+) cells. Preferential differentiation of E75-TCR(+)CD8(+)Perf(+) cells in distinct patients by AE-37 and AE-47 indicates that cancer vaccines will benefit from such correct individual and disease-associated help. Additional studies using the natural peptides p776 and F7 are needed to understand whether the LRMK-(Ava) tetra-, or pentamer augments or inhibits differentiation of CD8(+) cells, compared with native, natural HER-2 peptides and/or protects CD8(+) cells activated by E75 and by other HLA-I bound peptides from death. Our findings also develop a model for uniform quantification of differentiated CD8(+) effectors.
- 1 July 2009
- Vol. 29 (7) , 2427-35
N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells.
The objective of this study was to discover whether the peptides LRMK and LRMK-Ava linked to the N-terminus of peptides HER-2 (774-788) and HER-2 (776-788), respectively, help differentiation of E75-TCR(+)CD8(+) cells. Activation was quantified in terms of proliferation of E75-TCR(+)CD8(+) cells expressing high, medium and low density amounts of the specific TCR. Differentiation to functional CD8(+) cells was quantified as induction of Perforin (Perf), the lytic-enzyme which mediates the effector function of CD8(+) cells, in E75-TCR(+)CD8(+) cells. Peripheral blood mononuclear cells (PBMCs) of 3 patients activated with E75(+)AE-37 and E75(+)AE-47 more greatly increased the number of E75-TCR(Hi) CD8(+)Perf(+) cells than PBMCs activated by AE-47 alone or AE-47(+) E75. E75 plus cytokines and cytokines alone activated more E75-TCR(Low) cells than did AE-37 and AE-47. E75(+) AE-37 and AE-37 also induced differentiation of small- and medium-size activated CD8(+) cells from BRC ascites, in allogeneic activation, to Perf(+) cells. Preferential differentiation of E75-TCR(+)CD8(+)Perf(+) cells in distinct patients by AE-37 and AE-47 indicates that cancer vaccines will benefit from such correct individual and disease-associated help. Additional studies using the natural peptides p776 and F7 are needed to understand whether the LRMK-(Ava) tetra-, or pentamer augments or inhibits differentiation of CD8(+) cells, compared with native, natural HER-2 peptides and/or protects CD8(+) cells activated by E75 and by other HLA-I bound peptides from death. Our findings also develop a model for uniform quantification of differentiated CD8(+) effectors.